Skip to main content
. 2021 Jul 9;7(8):e724. doi: 10.1097/TXD.0000000000001179

TABLE 4.

Multivariate analysis of the effect of ABO incompatibility on acute (grade II–IV) and chronic (moderate-severe) graft-vs-host disease

Acute GVHD OR (95% CI) Chronic GVHD OR (95% CI)
Major ABO-Ia 1.18 (0.66-1.10)P = 0.5674 0.84 (0.48-1.49)P = 0.5684
Minor ABO-Ia 0.67 (0.33-1.33)P = 0.2596 0.83 (0.474-1.44)P = 0.5188
Bidirectional ABO-Ia 1.68 (0.82-3.44)P = 0.1489 1.13 (0.58-2.18)P = 0.7140
NMA conditioning 1.14 (0.72-1.82)P = 0.5557 0.87 (0.58-1.32)P = 0.5328
Haploidentical donorb 1.77 (0.67-4.63)P = 0.2422 1.60 (0.66-3.87)P = 0.2982
8/8 MUDb 1.48 (0.80-2.74)P = 0.2099 0.84 (0.49-1.45)P = 0.5434
7/8 MUDb 2.39 (1.13-5.06)P = 0.0225 0.52 (0.21-1.24)P = 0.1426
Female donor to male recipient 0.89 (0.45-1.78)P = 0.7590 1.12 (0.66-1.90)P = 0.6603
Bone marrow graft 0.58 (0.20-1.65)P = 0.3081 0.28 (0.10-0.76)P = 0.0125
CD34+ cells × 106/kg 1.04 (0.97-1.12)P = 0.1815 0.91 (0.84-0.99)P = 0.0383
CD3+ cells × 106/kg 0.99 (0.99-1.00)P = 0.7880 1.00 (0.99-1.00)P = 0.2066
Discordant CMV serology 1.06 (0.65-1.74)P = 0.7929 0.81 (0.50-1.30)P = 0.3916

Cell doses were considered as continuous variables.

Significant P values are highlighted in bold.

avs ABO-matched.

bvs HLA identical donor.

ABO-I, ABO incompatibility; CI, confidence interval; CMV, cytomegalovirus; GVHD, graft-vs-host disease; MUD, matched unrelated donor; NMA, nonmyeloablative; OR, odds ratio.